Covid19 Clinical Trial - A First Time in Human Phase 1 Open-Label Study of

Status Recruiting

Clinical Trial Summary

The main objectives of this study are to assess the safety, tolerability and immunogenicity of the candidate SARS-CoV-2 vaccines, COVIDITY, when administered using a needle-free injection device.

Clinical Trial Description

This is an open label, two-arm Phase 1 study to determine the safety, tolerability and immunogenicity of the SARS-CoV-2 COVIDITY vaccine, when administered using a needle-free injection device. COVIDITY consists of two doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 [doses 4 weeks apart]). A final end of study assessment will then be performed 6 weeks after last dose of study vaccine (Day 183 [earliest]). SCOV1 is expected to be active against the original SARS-CoV-2 strain and the B.1.1.7 (Alpha) variant, and to a slightly lesser extent against the B.1.351 (Beta) and P.1 (Gamma) variants. SCOV2 is expected to boost the effects of SCOV1 while providing further enhanced protection against the B.1.351 (Beta) and P.1 (Gamma) variants. Each dose of SCOV1 or SCOV2 will be administered via needle-free injection, either intradermally (0.2 mg doses; study Arm 1; PharmaJet Tropis® device) or intramuscularly (1.0 mg doses; study Arm 2; PharmaJet Stratis® device). Eligible injection sites include the outer aspect of the upper left or right arm (medial deltoid muscle) or the left or right outer thigh (lateralis muscle) for intradermal administration (Arm 1), and the outer aspect of the upper left or right arm (medial deltoid muscle) for intramuscular administration (Arm 2). This study is expected to enrol 40 participants (20 per study arm) at one study centre in South Africa. At least 15 participants in each arm should be negative for antibodies against SARS-CoV-2 upon entry into the study. ;

Study Design

Related Conditions & MeSH terms

COVID-19

Clinical Trial Details

NCT number	NCT05047445
Study type	Interventional
Source	Scancell Ltd
Contact	Robert Miller
Phone	+44 (0)1865 582 690
Email	[email protected]
Status	Recruiting
Phase	Phase 1
Start date	September 30, 2021
Completion date	June 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05047601` - A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual With Symptomatic COVID-19	Phase 3
Suspended	`NCT04394884` - Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)
Recruiting	`NCT04481633` - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection	N/A
Active, not recruiting	`NCT04537949` - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults	Phase 1/Phase 2
Active, not recruiting	`NCT04612972` - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru	Phase 3
Recruiting	`NCT04384445` - Zofin (Organicell Flow) for Patients With COVID-19	Phase 1/Phase 2
Recruiting	`NCT04341506` - Non-contact ECG Sensor System for COVID19
Recruiting	`NCT04512079` - FREEDOM COVID-19 Anticoagulation Strategy	Phase 4
Terminated	`NCT04498273` - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80	Phase 3
Enrolling by invitation	`NCT05089305` - Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection	Phase 2
Recruiting	`NCT04357990` - Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19	N/A
Recruiting	`NCT04528901` - Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)
Active, not recruiting	`NCT04527471` - Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT05041907` - Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)	Phase 2
Recruiting	`NCT05022329` - COVID-19 Vaccine Boosters in Patients With CKD	Phase 2/Phase 3
Not yet recruiting	`NCT04990466` - Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.	Phase 2/Phase 3
Recruiting	`NCT04661462` - Health After Covid-19 in Tyrol
Not yet recruiting	`NCT04446065` - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers	Phase 2/Phase 3
Recruiting	`NCT04526054` - Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients	N/A
Completed	`NCT04532931` - COVID-19 Treatment in South Africa	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms